N
Novo Nordisk A/S (NVO)
NYQ – Real vaqt narxi. Valyuta: USD
48.07
+0.43 (0.90%)
Yopilishda: Jun 26, 2026, 4:05 PM EDT
48.01
-0.06 (-0.12%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
48.07
+0.43 (0.90%)
Yopilishda: Jun 26, 2026, 4:05 PM EDT
48.01
-0.06 (-0.12%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
Novo Nordisk A/S, sho'ba korxonalari bilan birgalikda, farmatsevtika mahsulotlarini tadqiq qilish va ishlab chiqish, ishlab chiqarish va tarqatish bilan shug'ullanadi. U ikkita segment orqali faoliyat yuritadi: Semizlik va Diabetga G'amxurlik, va Kam Uchraydigan Kasalliklar. Semizlik va Diabetga G'amxurlik segmenti diabet, semizlik, yurak-qon tomir va boshqa rivojlanayotgan terapiya sohalari uchun mahsulotlar taqdim etadi. Kam Uchraydigan Kasalliklar segmenti kam uchraydigan qon kasalliklari, kam uchraydigan endokrin kasalliklar va gormon o'rnini bosuvchi terapiya sohalarida mahsulotlar taklif etadi. Kompaniya, shuningdek, NovoPen 6 va NovoPen Echo Plus, aqlli insulin qalamlarini; Dose Check, insulin dozasi bo'yicha ko'rsatmalar beruvchi ilovasini; o'sish gormoni qalamlari va in'ektsiya ignalarini; hamda Wegovy tabletkasini, vaznni boshqarish uchun og'iz orqali qabul qilinadigan glyukagon-o'xshash peptid-1 (GLP-1) retseptor agonisti terapiyasini taqdim etadi. U Yevropa, Kanada, Qo'shma Shtatlar, Yaponiya, Koreya, Okeaniya, Janubi-Sharqiy Osiyo, Xitoy materigi, Gonkong va Tayvan, Lotin Amerikasi, Yaqin Sharq va Afrikada faoliyat yuritadi. Novo Nordisk A/S 1923 yilda tashkil etilgan va shtab-kvartirasi Daniyaning Bagsvaerd shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Martin Holst Lange | EVP of R&D, Chief Scientific Officer and Member of the Management Board |
| Mr. Emil Kongshoej Larsen | EVP of International Operations & Member of Management Board |
| Mr. Jamey Millar | Executive VP of US Operations & Member of Management Board |
| Mr. John F. Kuckelman | SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board |
| Mr. Karsten Munk Knudsen | Executive VP, CFO & Member of the Management Board |
| Mr. Maziar Mike Doustdar B.A. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-24 | 6-K | f6k_062226.htm |
| 2026-06-22 | 11-K | nvo20251231c_11k.htm |
| 2026-06-15 | 6-K | f6k_061526.htm |
| 2026-06-08 | 6-K | f6k_060826.htm |
| 2026-06-01 | 6-K | f6k_060126.htm |
| 2026-05-27 | 6-K | f6k_052626.htm |
| 2026-05-22 | SD | dp247116_sd.htm |
| 2026-05-22 | 6-K | f6k_052226.htm |
| 2026-05-18 | 6-K | f6k_051826.htm |
| 2026-05-13 | 6-K | f6k_051226.htm |
| President, CEO & Member of the Management Board |
| Ms. Elin Jager | SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board |
| Ms. Hong Chow | Executive VP of Product & Portfolio Strategy and Member of Management Board |
| Ms. Tania Sabroe | EVP of People, Organisation and Corporate Affairs & Member of Management Board |
| Ms. Thilde Hummel Bogebjerg | Executive VP of Enterprise IT & Quality and Member of Management Board |